摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氨基-4-氟-2-甲基苯酚 | 122455-85-0

中文名称
5-氨基-4-氟-2-甲基苯酚
中文别名
——
英文名称
2-fluoro-5-hydroxy-4-methylaniline
英文别名
4-chloro-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline;5-amino-4-fluoro-2-methylphenol;4-amino-5-fluoro-2-hydroxytoluene;5-amino-4-fluoro-2-methyl-phenol;2-methyl-4-fluoro-5-aminophenol;5-amino-4-fluoro-2-methyl phenol
5-氨基-4-氟-2-甲基苯酚化学式
CAS
122455-85-0
化学式
C7H8FNO
mdl
MFCD04972656
分子量
141.145
InChiKey
HEAQOCBITATQEW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    147 °C
  • 沸点:
    271.0±35.0 °C(Predicted)
  • 密度:
    1.275±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    46.2
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R20/21/22
  • 海关编码:
    2922299090

SDS

SDS:fb6746c0af0d57ca48a43b5eb829c042
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-氨基-4-氟-2-甲基苯酚 生成 2-fluoro-4-methyl-5-(1-methylsulfanylpropan-2-yloxy)aniline
    参考文献:
    名称:
    FISCHER, REINER;MARHOLD, ALBRECHT;SCHALLNER, OTTO
    摘要:
    DOI:
  • 作为产物:
    描述:
    甲氧基甲酸(2-甲基-4-氟苯基)酯硫酸硝酸铁粉 、 iron(II) sulfate 作用下, 以 为溶剂, 反应 6.0h, 生成 5-氨基-4-氟-2-甲基苯酚
    参考文献:
    名称:
    一类新型有效的VEGF受体酪氨酸激酶抑制剂的设计与构效关系。
    摘要:
    合成了一系列取代的4-苯胺基喹唑啉和相关化合物,作为血管内皮生长因子(VEGF)受体(Flt和KDR)酪氨酸激酶活性的潜在抑制剂。酶筛查表明,对于双环系统而言,存在窄的构效关系(SAR),喹唑啉,喹啉和cinnolines具有活性,通常优选喹唑啉和喹啉。对苯胺的取代进行了研究,并清楚地表明,在C-4'位置优选使用较小的亲脂性取代基,例如卤素或甲基。在C-2'位置优选小的取代基,例如氢和氟。在苯胺的间位引入羟基会产生最有效的Flt和KDR酪氨酸激酶活性抑制剂,其IC(50)值在纳摩尔范围内(例如10、12、13、16和18)。对喹唑啉C-6和C-7位置的研究表明,在C-7可以容忍大范围的取代基,而C-6的变化受到更大的限制。在C-7处,中性,碱性和杂芳族侧链产生非常有效的化合物,如甲氧基乙氧基衍生物13(IC(50)<2 nM)所示。与与FGF受体相关的抑制剂(50至3800倍)相比,我们的
    DOI:
    10.1021/jm990345w
点击查看最新优质反应信息

文献信息

  • Compositions for oxidatively dyeing keratin fibers and methods for using such compositions
    申请人:Lim Mu'Ill
    公开号:US20070209123A1
    公开(公告)日:2007-09-13
    Compositions for dyeing keratin fibers comprise (a) at least one keratin dyeing compound selected from aromatic systems which comprise at least one boronic acid or boronic ester moiety and which are capable of forming upon oxidation a nucleophile or an electrophile, (b) at least one additional keratin dyeing compound selected from the group consisting of auxiliary developers and auxiliary couplers, and (c) a cosmetically suitable medium. Methods for oxidatively dyeing keratin fibers comprise the steps of applying such compositions in the presence of an oxidizing agent and rinsing the hair. A hair coloring product in kit form comprises a first separately packaged container comprising a composition as described above and a second separately packaged container comprising an oxidizing agent.
    用于染色的组合物包括:(a)至少一种选自含有至少一个硼酸或硼酸酯基团的芳香族系统的角蛋白染料化合物,这些化合物在氧化时能够形成亲核物或亲电子物;(b)至少一种额外的角蛋白染料化合物,选自辅助显色剂和辅助偶联剂的组合;(c)一种化妆品适用的介质。氧化染角蛋白纤维的方法包括在氧化剂存在下应用这样的组合物,并冲洗头发。一种套装形式的头发染色产品包括一个第一独立包装容器,其中包含上述描述的组合物,以及一个第二独立包装容器,其中包含氧化剂。
  • Quinoline derivatives inhibiting the effect of growth factors such as VEGF
    申请人:Zeneca Limited
    公开号:US06809097B1
    公开(公告)日:2004-10-26
    Compounds of the formula (I): wherein: R2 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; n is an integer from 0 to 5; Z represents —O—, —NH—, —S— or —CH2—; G1 represents phenyl or a 5-10 membered heteroaromatic cyclic or bicyclic group; Y1, Y2, Y3 and Y4 each independently represents carbon or nitrogen; R1 represents fluoro or hydrogen; m is an integer from 1 to 3; R3 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR4R5 (wherein R4 and R5, can each be hydrogen or C1-3alkyl), or a group R6—X1— wherein X1 represents —CH2— or a heteroatom linker group and R6 is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may have a heteroatom linker group, or R6 is an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans, processes for the preparation of such derivatives, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
    公式(I)的化合物: 其中:R2代表羟基,卤素,C1-3烷基,C1-3烷氧基,C1-3烷酰氧基,三氟甲基,氰基,氨基或硝基;n是0到5之间的整数;Z代表—O—,—NH—,—S—或—CH2—;G1代表苯基或一个5-10员的杂芳环状或双环状基团;Y1、Y2、Y3和Y4各自独立代表碳或氮;R1代表氟或氢;m是1到3之间的整数;R3代表氢,羟基,卤素,氰基,硝基,三氟甲基,C1-3烷基,—NR4R5(其中R4和R5各自可以是氢或C1-3烷基),或一个R6—X1—基团,其中X1代表—CH2—或一个杂原子连接基团,R6是一个烷基、烯基或炔基链,该链可选地被例如羟基、氨基、硝基、烷基、环烷基、烷氧基烷基或一个可选地被取代的吡啶酮、苯基和杂环环取代,该烷基、烯基或炔基链可能含有一个杂原子连接基团,或者R6是一个可选地被取代的吡啶酮、苯基和杂环环,以及它们的盐,用于制造一种药物,用于在温血动物如人类中产生抗血管生成和/或降低血管通透性的效果,制备这类衍生物的过程,包含公式I的化合物或其药物可接受的盐作为活性成分的药物组合物,以及公式I的化合物。公式I的化合物及其药物可接受的盐抑制VEGF的效果,这一特性在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值。
  • [EN] SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
    申请人:BAYER HEALTHCARE AG
    公开号:WO2009033581A1
    公开(公告)日:2009-03-19
    This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.
    这项发明涉及新颖化合物及其制备方法,治疗疾病的方法,特别是癌症,包括给予这些化合物,以及制备用于治疗或预防疾病,特别是癌症的药物组合物的方法。
  • Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
    申请人:Lim Mu'lll
    公开号:US20060156481A1
    公开(公告)日:2006-07-20
    Compositions for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and at least one N-oxides of six-membered rings with one or two nitrogen atoms keratin dyeing compound. A method for oxidative dyeing of keratin fibers, comprising applying such compositions in the presence of an oxidizing agent, for a period sufficient to develop the desired coloration.
    氧化染色角蛋白纤维的配方,包括适用于染色的介质和至少一种含有一个或两个氮原子的六元环N-氧化物的角蛋白染料化合物。一种氧化染色角蛋白纤维的方法,包括在氧化剂存在下施用这种配方,以足够时间发展所需的着色。
  • [EN] CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES<br/>[FR] AMIDES DE CYCLOPROPANE ET ANALOGUES PRÉSENTANT DES ACTIVITÉS ANTICANCÉREUSES ET ANTIPROLIFÉRATIVES
    申请人:DECIPHERA PHARMACEUTICALS LLC
    公开号:WO2010051373A1
    公开(公告)日:2010-05-06
    Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.
    本发明的化合物在治疗哺乳动物癌症,尤其是人类癌症方面具有实用性,包括但不限于恶性黑色素瘤、实体肿瘤、胶质母细胞瘤、卵巢癌、胰腺癌、前列腺癌、肺癌、乳腺癌、肾癌、肝癌、宫颈癌、原发肿瘤部位的转移、骨髓增生性疾病、慢性髓细胞白血病、白血病、乳头状甲状腺癌、非小细胞肺癌、间皮瘤、高嗜酸性综合征、胃肠道间质瘤、结肠癌、由高增殖导致失明的眼部疾病,包括各种视网膜病变、糖尿病视网膜病变、类风湿性关节炎、哮喘、慢性阻塞性肺病、肥大细胞增多症、肥大细胞白血病,以及由PDGFR-α激酶、PDGFR-β激酶、c-KIT激酶、cFMS激酶、c-MET激酶和致癌形式、异常融合蛋白和任何上述激酶的多态体引起的疾病。
查看更多